News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Thermo Fisher has equipped this Centre for Innovation with state-of-the-art platforms such as CellInsight CX7 LZR Pro High Content Screening Platform
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market
Subscribe To Our Newsletter & Stay Updated
